100% Quality Guarantee
PhD-Level Technical Support
Anti-CD37 naratuximab biosimilar mAb HDBS0046
Key Features

Naratuximab Biosimilar (CD37) Antibody (HDBS0046)

SKU HDBS0046
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein CD37
Reactivity Human
Host Species Humanized
Isotype IgG1
€431

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Naratuximab Biosimilar (CD37) Antibody (HDBS0046)

The CD37 Naratuximab Biosimilar Monoclonal Antibody (HDBS0046) is a cutting-edge product designed for research targeting the CD37 protein, which plays a crucial role in immune regulation and cancer cell growth. This biosimilar antibody, developed as a potential treatment for B-cell malignancies, exhibits high specificity and potency in targeting CD37-expressing cells.Through its unique mechanism of action, this monoclonal antibody effectively targets and eliminates cancerous cells while sparing healthy cells, minimizing side effects commonly associated with traditional cancer treatments. Its high affinity for CD37 makes it a promising candidate for precision medicine approaches in cancer therapy.

This biosimilar monoclonal antibody is a valuable tool for researchers studying CD37 biology, tumor immunology, and targeted cancer therapies. Its ability to selectively target cancer cells and modulate immune responses makes it a key player in the development of novel treatment strategies for hematological malignancies.Overall, the anti-CD37 Naratuximab Biosimilar Monoclonal Antibody (HDBS0046) represents a promising advancement in cancer research and immunotherapy, offering new possibilities for personalized and effective cancer treatment options.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose